Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus modified TPF and concurrent chemoradiotherapy for stage IVa nasopharyngeal carcinoma
ChiCTR2200060097Phase 2Recruiting
- Sponsor
- Yulin First People's Hospital
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Yulin First People's Hospital. Primary endpoint: 3-year progression-free survival. Started Jun 2022; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2200060097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060097.